What is Asceneuron?
Founded in 2012 and headquartered in Lausanne, Switzerland, Asceneuron is dedicated to discovering and developing novel small molecules designed to halt and prevent the molecular events that drive neurodegeneration. The company targets high unmet medical needs in neurological disorders, including orphan tauopathies, Alzheimer's disease, and Parkinson's disease. Asceneuron's strategic focus on addressing the root causes of these debilitating conditions positions it as a key player in the race for effective neurodegenerative therapies.
How much funding has Asceneuron raised?
Asceneuron has raised a total of $130.6M across 2 funding rounds:
Series A
$30.6M
Series C
$100M
Series A (2015): $30.6M with participation from SR One, Sofinnova Partners, Kurma Partners, and MS Ventures
Series C (2024): $100M led by OrbiMed, SR One, and Novo Holdings
Key Investors in Asceneuron
OrbiMed
OrbiMed is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health. They support companies at various stages of development, from early-stage ventures to established organizations scaling solutions.
SR One
SR One is a transatlantic biotechnology venture capital firm investing in early and growth-stage life sciences companies developing novel therapeutics. They provide hands-on strategic and operational support to translate innovative technologies into new medicines.
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, established in 1999. It is a significant investor in the life sciences sector.
What's next for Asceneuron?
The recent major strategic investment in Asceneuron signals a pivotal stage for the company, likely enabling accelerated clinical development and potential commercialization efforts. This significant capital infusion, following its Series A financing, suggests a transition towards later-stage development and market readiness. Asceneuron is poised to leverage this backing to advance its pipeline of innovative small molecules, aiming to bring transformative treatments to patients suffering from severe neurodegenerative diseases.
See full Asceneuron company page
